<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980135</url>
  </required_header>
  <id_info>
    <org_study_id>13932</org_study_id>
    <secondary_id>2008-008136-82</secondary_id>
    <nct_id>NCT00980135</nct_id>
  </id_info>
  <brief_title>Sinecort Pilot Efficacy Study</brief_title>
  <acronym>Sinecort Pilot</acronym>
  <official_title>An Investigator-blind, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a New Topical Medical Device in Patients With Mild Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study shall prove whether treatment of atopic dermatitis is equally effective with
      Sinecort cream as compared to standard therapy (Hydrocortisone cream).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy rate versus comparator and untreated skin</measure>
    <time_frame>After 29 days of twice daily applications</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local side effects on the skin</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local SCORAD as clinical assessment by means of the intensity items of the SCORAD index) at Visit 2 through Visit 6</measure>
    <time_frame>after 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal water loss (TEWL) as a measure for skin barrier function at Visit 2 through Visit 6</measure>
    <time_frame>after 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin hydration by means of corneometry at visit 2 through visit 6</measure>
    <time_frame>after 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema by means of chromametry at Visit 2 through Visit 6</measure>
    <time_frame>after 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of pruritus at each day of the dosing period (day 1- day 29) as reported in the patients diary and at Visit 2 through Vist 6 by means of visual analogue scale (VAS)</measure>
    <time_frame>after 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Event</measure>
    <time_frame>visit 2 (start of dosing period) till 6 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>visit1 and 6 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local side effects</measure>
    <time_frame>visit 2 (start of dosing period) till 6 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinecort cream</intervention_name>
    <description>Application over 29 days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortison cream</intervention_name>
    <description>Application over 29 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Untreated skin</intervention_name>
    <description>n.a</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Caucasians aged between 18 and 65 years

          -  Patients with mild AD presenting a scoring AD (SCORAD) rating between 3-25

          -  Skin type I - IV according to Fitzpatrick

          -  Acute AD symptoms on each assessment areas (local SCORAD &gt;/=3 and &lt;= 12)

          -  Acute symptom of pruritus at Baseline

        Exclusion Criteria:

          -  Any other skin disease at the test area that would interfere the clinical assessment
             in the opinion of the investigator

          -  Moles, tattoos, strong pigmentation, or scars at the test area that would interfere
             the clinical assessment

          -  Regular intake of antiphlogistic drugs (for example, NSAIDs)

          -  Any condition or treatment which might influence the trial (e.g. any treatment with
             topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as
             well as during the trial (exception: topical treatment of AD lesions other than the
             test areas (for example, face) with low potency steroids restricted to small areas)

          -  UV-therapy or the use of solarium within 30 days before screening as well as during
             the trial

          -  Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy)
             within 30 days before screening as well as during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>MÃ¼nster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sinecort</keyword>
  <keyword>Hydrocortison</keyword>
  <keyword>Mild atopic dermatitis</keyword>
  <keyword>Efficacy, safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

